The multifactorial nature of complex diseases requires flexible, accurate solutions to identify molecular targets. Illumina offers tools to understand the relationship between genotype and phenotype of complex disease, driving discovery of potential biomarkers and therapeutic targets to develop new treatments.
With the sensitivity, accuracy, and speed of array and NGS solutions, researchers can identify causative variants of complex diseases rapidly. Our complete solutions facilitate profiling of the genome, transcriptome, and epigenome, even with limited material available from clinical specimens.
TruSight Sequencing Panels: Designed for translational research, these panels comprise oligo probes targeting genes and regions thought to be relevant for particular diseases or conditions.
TruSight One: Provides comprehensive coverage of more than 4800 clinically relevant genes.
TruSight HLA: Enables high-resolution, phase-resolved sequencing of 11 HLA loci.
TruSight Cardio: Designed to identify causal variants implicated in inherited cardiac conditions.